Results 51 to 60 of about 6,775 (167)

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL [PDF]

, 2018
Early data on venetoclax-containing regimens for the treatment of chronic lymphocytic leukemia (CLL) show promising results with deep remissions, but are hampered by potential risk for tumor lysis syndrome (TLS).
Kersting, S, Kater, Arnon P., Croon-de Boer, Fransien, Hoogendoorn, M, Dubois, J, Schreurs, John, Dobber, Johan A., Evers, Ludo M., Visser, Hein, Levin, M-D, Schreurs, J, van Norden, Yvette, Tonino, Sanne H., van der Spek, E, Idink, Cecile, Evers, LM, Mobasher, Mehrdad, Kater, AP, Mellink, Clemens H., Boer, F, Visser, H, Wittebol, S, Dubois, Julie, Idink, C, van der Spek, Ellen, Levin, Mark-David, Kersting, Sabina, Mobasher, M, Tonino, SH, Dobber, JA, Mellink, CH, Wittebol, Shulamiet, Hoogendoorn, Mels   +32 more
core   +1 more source

Response‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort

British Journal of Haematology, EarlyView.
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff, Fabian Görke, Vanja Zeremski, Sophia Wollnitza, Evgenii Shumilov, Georg Lenz, Ellen Obstfelder, Inken Hilgendorf, Vladan Vučinić, Andreas Hochhaus, Ulf Schnetzke   +10 more
wiley   +1 more source

Real‐world effectiveness and safety of acalabrutinib in chronic lymphocytic leukaemia: Multicentre experience

British Journal of Haematology, EarlyView.
Summary Chronic lymphocytic leukaemia (CLL) primarily affects elderly patients with comorbidities, yet real‐world data on acalabrutinib, a second‐generation Bruton's Tyrosine Kinase (BTK) inhibitor, remain limited outside clinical trials, particularly in Italy.
Andrea Duminuco, Dario Leotta, Alessandro Allegra, Daniele Caracciolo, Laura Caruso, Annalisa Chiarenza, Vittorio Del Fabro, Valentina Di Martina, Amalia Figuera, Paolo Fabio Fiumara, Massimo Gentile, Vanessa Innao, Salvatrice Mancuso, Enrica Antonia Martino, Antonio Mosca, Giovanna Motta, Francesca Pedalino, Marco Rossi, Fabio Stagno, Giorgio Tona, Francesco Di Raimondo, Giuseppe Alberto Palumbo   +21 more
wiley   +1 more source

Simultaneous determination of venetoclax and obinutuzumab by LC-MS/MS and its application to pharmacokinetic drug interaction studies [PDF]

Brazilian Journal of Pharmaceutical Sciences
A novel LC-MS/MS method was developed and validated for the simultaneous quantification of venetoclax and obinutuzumab in rat plasma and successfully applied to pharmacokinetic investigations in male wistar rats.
Modachakanahally K Pavithra, Hemavathi Nagaraju Deepakumari, Ere Vijaya Sekhar, Hosakere Doddarevanna Revanasiddappa, Razia Sulthana   +4 more
doaj   +2 more sources

Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients

Transplantation Direct, 2023
Background. The THEORY study evaluated the effects of single and multiple doses of obinutuzumab, a type 2 anti-CD20 antibody that induces antibody-dependent cell-mediated cytotoxicity and direct cell death, in combination with standard of care in ...
Cary M. Looney, MS, Aaron Schroeder, BS, Erica Tavares, BSN, Jay Garg, MD, MBA, Thomas Schindler, PhD, Flavio Vincenti, MD, Robert R. Redfield, MD, Stanley C. Jordan, MD, Stephan Busque, MD, E. Steve Woodle, MD, Jared Khan, MS, Jeffrey Eastham, MS, Sandrine Micallef, PhD, Cary D. Austin, MD, PhD, Alyssa Morimoto, PhD   +14 more
doaj   +1 more source

Clinical outcomes of the chemo‐free approach in relapsed/refractory follicular lymphoma: A network meta‐analysis

British Journal of Haematology, EarlyView.
Graphical overview of the network meta‐analysis (NMA) evaluating chemo‐free approaches for relapsed/refractory follicular lymphoma (R/R FL). Epcoritamab plus rituximab (R2) achieved the highest cumulative ranking probability (SUCRA) across efficacy end‐points but increases the risk of predictable toxicity over anti‐CD20 monotherapy.
Daniele Caracciolo, Maria Rita Lombardo, Gianluca Reitano, Cristina Napoli, Lucia Fiorillo, Chiara Callerame, Mario Garritano, Alessio Bulotta, Maha Munir, Giulia Pensabene, Emiliano Barbieri, Alberto Bavieri, Pierfrancesco Tassone, Pierosandro Tagliaferri, Stefano Luminari   +14 more
wiley   +1 more source

Impact of obinutuzumab alone and in combination for follicular lymphoma [PDF]

, 2017
Maryam Sarraf Yazdy, Bruce D Cheson Division of Hematology-Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC, USA Abstract: Although rituximab-based chemoimmunotherapy prolongs the survival of patients ...
Sarraf Yazdy M, Cheson BD
core  

Pharmacokinetics of obinutuzumab in Chinese patients with B-cell lymphomas [PDF]

, 2017
AIM The Phase Ib GERSHWIN study (NCT01680991) assessed the pharmacokinetic (PK) profile of obinutuzumab following multiple intravenous (i.v.) doses to Chinese patients with B-cell lymphomas, and compared findings with previous obinutuzumab PK studies ...
Qin, Yan, Du, Xin, Shen, Zhixiang, Shi, Yuankai, Song, Yuqin, Shi, Jun, Zhu, Jun, Zhai, John, Jamois, Candice, Brewster, Michael   +9 more
core   +1 more source

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma. [PDF]

, 2022
This phase I study evaluated safety, tolerability and preliminary efficacy of obinutuzumab in combination with venetoclax in patients with previously untreated grade 1-3a follicular lymphoma in need of systemic therapy. Two dose levels of venetoclax were
Mey, Ulrich, Hiddemann, Wolfgang, Unterhalt, Michael, Rossi, Davide, Ceriani, Luca, Zucca, Emanuele, Stathis, Anastasios, Dirnhofer, Stefan, Moccia, Alden A, Buske, Christian, Hitz, Felicitas, Hohloch, Karin, Kienle, Dirk Lars, Krasniqi, Fatime, Hess, Dagmar, Hayoz, Stefanie, Eckhardt, Katrin, Moccia, Alden A., Mey, Ulrich J M, Mach, Nicolas, Bertoni, Francesco, Schär, Sämi, Forestieri, Gabriela, Schmidt, Christian, Sartori, Giulio, Pott, Christiane, Novak, Urban   +26 more
core   +1 more source

Research advances of obinutuzumab in the treatment of membranous nephropathy

Linchuang shenzangbing zazhi
Membranous nephropathy （MN） is a common cause of adult nephrotic syndrome. Rituximab, a type Ⅰ anti-CD20 monoclonal antibody, is an effective treatment of MN.
Xiao-jing Lin, Jing Sun, Hao-yi Xiangli, Xuan-yi Du   +3 more
doaj   +1 more source